U.S. Pharmaceutical CDMO for Formulations Market - Databook 2025 to 2034

The U.S. pharmaceutical CDMO for formulations market size surpassed USD 10.15 billion in 2024 and is predicted to reach around USD 21.92 billion by 2034, registering a CAGR of 8% from 2025 to 2034.

Highlights of the U.S. Pharmaceutical CDMO for Formulations Market

• By dosage form, the oral solids segment dominated the U.S. pharmaceutical CDMO for formulations market in 2024.
• By dosage form, the injectables segment is observed to grow at the fastest rate in the pharmaceutical CDMO for formulations market during the forecast period.
• By therapeutic area, the oncology segment dominated the U.S. pharmaceutical CDMO for formulations market in 2024.
• By therapeutic area, the infectious diseases segment is observed to grow at the fastest rate in the U.S. pharmaceutical CDMO for formulations market during the forecast period.
• By end user, the pharmaceutical companies segment dominated the U.S. pharmaceutical CDMO for formulations market in 2024.
• By end user, the biopharmaceutical companies' segment is observed to grow at the fastest rate in the U.S. pharmaceutical CDMO for formulations market during the forecast period.

Industry Valuation and Growth Rate Projection

CDMOs support pharmaceutical firms at all stages of the procedure of making medicines: by offering services in the R&D stages, by providing support in manufacturing, and by offering formulating and finishing procedures. CDMOs have been growing in the last decade, with a progressively dynamic mergers and acquisitions (M&A) landscape boosted by consolidation.

Market Trends

• The requirement for outsourcing services is increasing due to the demand for cost-effective drug advancement and producing compliant with regulatory standards.
• The increasing demand for biosimilars and biologics is boosting growth in the CDMO market, as these therapies need specialized expertise and production capabilities.
• Artificial intelligence is becoming progressively implemented into CDMO processes, accelerating research, streamlining operations, and facilitating data analysis.

Restraints

• CDMOs must stick to strict global regulations presiding over drug development, quality control, and production practices, which can be expensive and time-consuming. Evolving regulatory requirements over different regions thus complicates the landscape.
• Establishing or upgrading facilities, mainly biologics and sterile manufacturing, demand remarkable financial investment.
• Shifting client expectations, thus faster turnaround times and personalized solutions, set pressure on CDMOs to accept and innovate.

Opportunities

• CDMOs can grip their expertise in specialized areas such as biologics, sterile liquids, and advanced therapies.
• CDMOs can assist pharmaceutical firms reduce manufacturing expenses and streamline production.
• Providing implemented services via the drug advancement and manufacturing process provides a competitive advantage.
• CDMOs assure adherence to regulatory standards, guranteeing drug development and manufacturing.

Recent Developments in the U.S. Pharmaceutical CDMO for Formulations Market

• In September 2024, PCI Pharma Services is perfusing more than $365 million in infrastructure understanding the clinical and commercial-scale final assembly and packaging of drug-device combination goods using advanced drug delivery systems, with a focus on injectable formats

U.S. Pharmaceutical CDMO for Formulations Market Companies:

• Lonza
• Catalent, Inc.
• Thermo Fisher Scientific (Patheon)
• Cambrex Corporation
• Veranova
• Fujifilm Diosynth Biotechnologies
• WuXi Biologics
• PCI Pharma Services
• Adare Pharma Solutions
• CordenPharma

U.S. Pharmaceutical CDMO for Formulations Market Segmentation:

By Dosage Form

• Oral Solids 
• Oral Liquids 
• Injectables 
• Topicals 
• Inhalation Products 
• Transdermal And Patches 
• Others 

By Therapeutic Area

• Oncology 
• Cardiology 
• Central Nervous System 
• Gastroenterology
• Infectious Diseases 
• Endocrinology (Diabetes, Hormonal Therapy)

By End User

• Pharmaceutical Companies 
• Biopharmaceutical Companies 
• Others